Tata Consultancy Services Solution, Part of TCS ADD™ Analytics and Insights, Uses Machine Learning and AI to Remotely Monitor Study and Site Risks, and Improves Study Efficacy
MUMBAI, April 18, 2022: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has launched an agile and intuitive risk-based monitoring solution for clinical trials, that enables intelligent decision making, increased compliance and improves study efficacy.
Part of the TCS ADD™ suite, the new risk-based monitoring solution enables biopharmaceutical and Contract Research Organizations (CROs) to identify study and site risks through advanced statistical algorithms and drive intelligent data driven decisions. The data science led risk-based monitoring solution precisely predicts outcomes pertaining to site workload and risks, thereby enabling stakeholders to lay out proactive monitoring strategies.
The risk-based monitoring solution comprises:
- Intelligent risk management that facilitates automated triggers for outliers with advanced analytics and visualizations.
- AI/ML based predictive analytics with leading indicators of site monitoring workload analytics.
- 40+ operational metrics across study, site, subject, data management and budget management categories, providing a holistic performance view across site, country, region, study, program, compound and therapeutic area.
- A one-click communication module that provides a unified and collated list of pending activities, and system generated intelligent actions across all source systems; driving greater engagement and collaboration.
The novel and intuitive Risk Based Monitoring solution provides insights into missing data, improving data quality and consistency, and enabling early identification of trends and outliers. Sponsors and CROs are expected to realize up to 30% efficiency gain in site monitoring through the solution. In addition, automation speeds up the process, reduces site workload, improves overall compliance, and contributes to product speed-to-market.
“With COVID 19 critically impacting site visits, life sciences industries realized the value of remote Risk Based Monitoring solutions that empower sponsors to monitor trials centrally, assess the risks and track corrective actions to enhance study quality,” said Debashis Ghosh, Business Group Head, Life Sciences Healthcare, and Public Services, TCS. “With our deep domain knowledge of the life sciences industry, we are continually expanding the capabilities of our modern and open TCS ADD platform to include data science, artificial intelligence and machine learning led clinical operational analytics solutions that transform the drug development value chain, deliver greater value for our customers and achieve faster compliance.”
About TCS ADD™ Platforms
TCS ADD™ provides a suite of modern and open drug development platform for life sciences that enables digital ecosystems, simplifies data complexity and provides faster access to new and effective drugs for patients in need. The platform is powered by our proprietary cognitive intelligence engine, data driven smart analytics and Internet of Things (IoT) that makes clinical trials more agile and safe. TCS ADD leverages the best of cloud architecture and personalized user experience design in compliance with quality guidelines and privacy regulations.
About Tata Consultancy Services (TCS)
Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.
A part of the Tata group, India's largest multinational business group, TCS has over 592,000 of the world’s best-trained consultants in 46 countries. The company generated consolidated revenues of US $25.7 billion in the fiscal year ended March 31, 2022 and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit www.tcs.com.
TCS media contacts
Phone: +65 9695 9948
Australia and New Zealand
Phone: +61 422 989 682
Phone: +1 647 790 7602
Phone: +31 615 903387
Phone: +91 22 67789098
Phone: +91 22 6778 9999
Middle East & Africa
Phone: +81 80 2115 0989
Phone: +521 55 2095 6098
Phone: +44 20 3155 2421
Phone: +1 917 981 7651